Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

NCT02586233 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02586233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02586233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2015
Completion date
August 13, 2019
Enrollment
106 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, thrombotic disease